World-wide Companion Diagnostics Marketplace Prospect Investigation and Market Forecast Report 2021
The “Companion Diagnostics Market place by Know-how Style, by Indicator – International Option Analysis and Marketplace Forecast, 2020 – 2030” report has been extra to ResearchAndMarkets.com’s supplying.
The World-wide Companion Diagnostics Market place dimensions was valued at USD 1.96 billion in 2019 and is predicted to reach USD 9.02 billion by 2030, with a CAGR of 14.8% from 2020-2030.
Companion Diagnostic (CDx) is a clinical exam co-made with a therapeutic drug for screening the responders and non-responders to that distinct drug. It is completed in get to discover a affected person group that can or are not able to be taken care of with that corresponding drug. CDx aids practitioners to figure out the added benefits, aspect outcomes, and dangers associated with the intake of therapeutic prescription drugs, thereby ensuring patient’s security.
Industry Dynamics and Traits:
The increasing tastes for specific therapies, escalating programs of customized medications, greater prevalence of persistent conditions, and growing incidences of allergic reactions in individuals because of to aspect effects of medications give rise to progress of personalized CDx, therefore propagating the development of world Companion Diagnostics industry Moreover, the positive aspects presented by CDx take a look at this kind of as charge-performance, superior sensitivity, speedy and accurate success in less time frames further more escalates the growth of Companion Diagnostics sector.
According to information offered by Entire world Health Firm in 2018 1 in 6 deaths are prompted thanks to most cancers every single calendar year. At worldwide level, an believed 6.8 million men and women die every single yr suffering from neurological problems. CDx retains extensive application for indication, in serious problems these kinds of as oncology, neurology, and other folks.
This state of affairs further more health supplements the advancement of international Companion Diagnostics marketplace. On the other hand, costly R&D procedures to produce new CDx, and unfavorable reimbursement insurance policies, restricts the expansion of world Companion Diagnostics industry. On the other hand, upsurge in R&D things to do, and growing amount of approvals granted by the U.S Foodstuff Drug Administration (Fda), are predicted to propagate the growth of world wide Companion Diagnostics market place in coming potential.
Geographical Investigation:
North America is predicted to dominate the world wide companion diagnostics marketplace, in the course of the forecast interval, accounting for the maximum market place share. This is attributed to effectively-established health care infrastructures and professional medical laboratories, improved investments in R&D routines to develop advanced companion diagnostics, as properly as escalating preferences in the direction of individualized medicinal therapies in this region.
Asia Pacific area is expected to increase substantially in the world-wide companion diagnostics sector, with the highest CAGR values, owing to increasing health care services, greater geriatric population susceptible to most cancers & neurological disorders, as well as increasing healthcare tourism in this area.
Aggressive Landscape:
The companion diagnostics market is highly competitive and is composed of many industry gamers. Some of the main industry players involve Abbott Laboratories Molecular, Inc., ARUP Laboratories, Inc., Agilent (Dako Denmark A/S), Danaher Corporation (Leica Microsystems), BioMerieux SA, Basis Medication, Inc., Qiagen N.V., Myriad Genetics, Inc., Thermo Fisher Scientific (Lifestyle Technologies Corporation), and Roche (Ventana Healthcare Devices, Inc.) between many others.
The crucial players are utilizing methods these kinds of as joint ventures for co-establishing new products and solutions, and acquisitions, in-buy to attain more robust placement in the companion diagnostics sector.
For occasion, in March 2020, Thermo Fisher Scientific, one of the major gamers of companion diagnostics market, declared the signing of an agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, to co-develop a CDx for cancer. Thermo Fisher’s Oncomine Dx Goal Examination contains 46 most cancers-related biomarkers for detection of each DNA and RNA variants. Its workflow functions fast turnaround time and cheapest sample necessities as in contrast to common oncology checks.
In June 2020, Thermo Fisher Scientific, introduced that it has extended its strategic partnership with Agios Prescription drugs, by signing an extended arrangement to co-establish a worldwide CDx for Low-Grade Glioma (LGG) in oncology. This CDx examination includes the identification of IDH gene mutations making use of the Ion Torrent Genexus Program and Oncomine Precision Assay exam, for LGG sufferers.
Key Matters Protected:
1. Introduction
1.1. Report Description
1.2. Research Methodology
2. Marketplace Snapshot, 2019-2030 Million USD
2.1. Market Snapshot
3. Porter’s Five Power Design Investigation
4. Sector Dynamics
4.1. Advancement Motorists
4.2. Problems
4.3. Chances
5. World-wide Companion Diagnostics Current market, by Technological know-how
5.1. Overview
5.2. Immunohistochemistry
5.3. Polymerase Chain Reaction (Pcr)
5.4. Subsequent Technology Sequencing (Ngs)
5.5. in Situ Hybridization
5.6. Other Technologies
6. International Companion Diagnostics Market place, by Indication
6.1. Overview
6.2. Oncology
6.2.1 World wide Oncology Market, by Indicator
6.2.1.2 Colorectal Most cancers Market place, by Region
6.2.1.3 Breast Cancer Market place, by Region
6.2.1.4 Blood Cancer Sector, by Area
6.2.1.5 Other individuals Market place, by Area
6.2.2 Oncology Market, by Area
6.3. Neurology
6.4. Other Indication
7. International Companion Diagnostics Sector, by Location
8. Firm Profiles
8.1 Firm Overview
8.2 Firm Snapshot
8.3 Working Organization Segments
8.4 Products Portfolio
8.5 Company Overall performance
8.6 Important Strategic Moves and Progress
-
Abbott Laboratories Molecular, Inc.
-
ARUP Laboratories, Inc.
-
Agilent (Dako Denmark A/S)
-
Danaher Company (Leica Microsystems)
-
BioMerieux SA
-
Basis Medication, Inc.
-
Qiagen N.V.
-
Myriad Genetics, Inc.
-
Thermo Fisher Scientific (Lifestyle Systems Company)
-
Roche (Ventana Clinical Devices, Inc.)
For a lot more information about this report stop by https://www.researchandmarkets.com/r/p67xd3
Look at resource model on businesswire.com: https://www.businesswire.com/news/dwelling/20210426005472/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Push Manager
[email protected]
For E.S.T Business office Several hours Contact 1-917-300-0470
For U.S./CAN Toll Free of charge Connect with 1-800-526-8630
For GMT Business Hrs Connect with +353-1-416-8900